Laboratory Corporation of America Holdings

NYSE LH

Download Data

Laboratory Corporation of America Holdings Operating Cash Flow to Debt Ratio for the Trailing 12 Months (TTM) ending March 31, 2024: -0.01

Laboratory Corporation of America Holdings Operating Cash Flow to Debt Ratio is -0.01 for the Trailing 12 Months (TTM) ending March 31, 2024, a -107.29% change year over year. The operating cash flow to debt ratio measures the ability of a company's operating cash flow to cover its total debt obligations. It is calculated by dividing the operating cash flow by the total debt. This ratio provides insights into the company's ability to generate cash flow from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating cash flow relative to the level of debt, suggesting potential financial strength and debt servicing capability.
  • Laboratory Corporation of America Holdings Operating Cash Flow to Debt Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.08, a -24.44% change year over year.
  • Laboratory Corporation of America Holdings Operating Cash Flow to Debt Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.10, a -21.56% change year over year.
  • Laboratory Corporation of America Holdings Operating Cash Flow to Debt Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.13, a 133.88% change year over year.
  • Laboratory Corporation of America Holdings Operating Cash Flow to Debt Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.06, a 10.64% change year over year.
NYSE: LH

Laboratory Corporation of America Holdings

CEO Mr. Adam H. Schechter
IPO Date March 29, 1990
Location United States
Headquarters 358 South Main Street, Burlington, NC, United States, 27215
Employees 67,000
Sector Healthcare
Industry Diagnostics & research
Description

Labcorp Holdings Inc. operates as a laboratory services company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers.

Similar companies

WAT

Waters Corporation

NA

NA

HOLX

Hologic Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email